17:39 EST Rhythm Pharmaceuticals (RYTM) files automatic mixed securities shelf
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals: Imcivree Momentum and Bivamelanotide Pipeline Catalysts Underpin Buy Rating and $130 Target
- Rhythm Pharmaceuticals reports Q4 EPS (73c), consensus (78c)
- Shopify, eBay upgraded: Wall Street’s top analyst calls
- Rhythm Pharmaceuticals initiated with an Outperform at RBC Capital
- Rhythm’s LB54640 Trial Completion Sets Up Key Catalyst in Hypothalamic Obesity